[A19-80] Elotuzumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V

Last updated 02.01.2020

Project no.:

Commission awarded on 20.09.2019 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:


Adult patients with relapsed and refractory multiple myeloma after at least 2 prior therapies (including lenalidomide and a proteasome inhibitor) and disease progression on the last therapy

Result of dossier assessment:

Only positive effects (in mortality and side effects), indication of minor added benefit


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

informedhealth.org logo Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Federal Joint Committee (G-BA)

2020-04-02 A G-BA decision was published.

G-BA documents on this decision


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form